Trial Profile
Randomized Trial of Paroxetine-CR for the Treatment of Patients With Post-Traumatic Stress Disorder (PTSD) Remaining Symptomatic After Initial Exposure Therapy.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 18 Jul 2023
Price :
$35
*
At a glance
- Drugs Paroxetine (Primary)
- Indications Post-traumatic stress disorders
- Focus Therapeutic Use
- 01 Mar 2008 Results presented in the Journal of Clinical Psychiatry.
- 08 Jan 2007 Status change
- 21 Jan 2006 New trial record.